+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Parkinson's Disease - Market Insight, Epidemiology and Market Forecast - 2032

  • PDF Icon

    Report

  • 285 Pages
  • January 2024
  • Region: Global
  • DelveInsight
  • ID: 4401843

Quick Summary:

In an increasingly fragmented and dynamic healthcare landscape, the need for comprehensive and forward-looking market insights has never been more crucial. That is where the “Parkinson's disease - Market Insights, Epidemiology and Market Forecast- 2032” report proves an invaluable tool for senior business executives. It provides an in-depth understanding of the Parkinson's disease market in the United States, European Union 4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Going beyond a mere data dump, this report offers actionable insights into current treatment practices, unmet patient needs, and market potential, delivering strategic value for informed decision-making and planning.

Gleaning insights from the extensive epidemiology data, the report shows that the majority of diagnosed prevalent Parkinson's Disease patients were found in the US, followed by the EU4, UK, and Japan. Changing demographics and the projected increase of diagnosed patients sets the stage for market growth in the forecast period. Similarly, the report explores the robust pipeline of emerging treatments, including therapies from Cerevel Therapeutics and Biogen amongst others, that promise to redefine the treatment landscape. Notably, the report also tracks patterns of gender discrepancies in the disease, highlighting nuanced factors that may impact the market. Be ahead of the curve and unlock the power of strategic decision-making with this data-rich yet easy-to-digest report.

Covers the Therapeutics Market Revenue, Treatment Practice/Algorithm and Forecasted Market Size of Parkinson's Disease (PD) from 2017 to 2025 Segmented by Seven Major Markets

Key Highlights

  • The diagnosed prevalence of Parkinson's disease has been increasing in the US due to the increasing geriatric population and disease awareness.
  • Increased awareness and ongoing research have led to a better understanding of Parkinson's disease and the discovery of innovative treatments, including gene therapy, stem cell therapy, and disease-modifying therapy.
  • The diagnosis of Parkinson's disease is challenging due to higher chances of misdiagnosis and overlapping symptoms with atypical Parkinsonian syndromes like Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), Dementia with Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), and other brain disorders. Further, the lack of effective diagnostic measurement tools and devices delays the diagnosis.
  • The treatment of Parkinson's involves pharmacological and nonpharmacological options, tailored together to alleviate the symptoms of Parkinson's disease and help improve quality of life. Although it lacks curative therapy, several classes of medication, including levodopa, dopamine agonists, Monoamine oxidase-B (MAO-B) inhibitors, Catechol-o-methyltransferase (COMT) inhibitors, amantadine, anticholinergics, and adenosine A2A antagonists are widely used to treat Parkinson's disease.
  • Levodopa is the gold standard for the treatment of Parkinson's disease; however, other medications are needed because patients on levodopa develop motor fluctuations and dyskinesia.
This “Parkinson's Disease - Market Insights, Epidemiology, and Market Forecast - 2032” report delivers an in-depth understanding of the Parkinson's disease historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Parkinson's disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Parkinson's disease market size from 2019 to 2032. The report also covers current Parkinson's disease treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan
Study Period: 2019-2032

Parkinson's Disease Understanding and Treatment Algorithm

Parkinson's Disease Overview

Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra and primarily affects movement.

The motor symptoms of Parkinson's disease include tremors, bradykinesia (slowness of movement), rigidity, and postural instability, while the non-motor symptoms may include cognitive impairment, mood disorders, sleep disturbances, and autonomic dysfunction. These symptoms can severely affect a patient's quality of life if uncontrolled. Additionally, caregiver burden is significant due to the progressive nature of the disease.

The cause of Parkinson's disease remains unknown, but it has long been hypothesized that exposure to environmental risk factors may be one cause, along with an inherited susceptibility. While men are slightly more susceptible than women are, it typically affects individuals over the age of 60, but early-onset cases also occur.

Parkinson's Disease Diagnosis

Diagnosing Parkinson's disease can be challenging, as there is no definitive test for the condition. However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson's - particularly in its early stages - is difficult, but a skilled practitioner can conclude it is Parkinson's disease. To avoid misdiagnosis, consultation with a movement disorder specialist (MDS) is recommended.

Further details related to country-based variations are provided in the report.

Parkinson's Disease Treatment

The medications used to treat Parkinson's disease include levodopa, dopamine agonists, MAO-B inhibitors (MAO-B), catechol-O-methyl transferase (COMT) inhibitors, amantadine, and anticholinergics. The main goal of these medications is to lessen motor symptoms or the symptoms that affect movement in people with Parkinson's disease. Several US FDA-approved medications such as XADAGO, DUOPA/DUODOPA, INBRIJA, ONGENTYS, and others are also being used to treat motor and non-motor symptoms associated with Parkinson's disease. In addition, several other approaches are also recommended including deep brain stimulations, physical and occupational therapies, speech therapy, and exercise programs.

Levodopa is the gold standard for the treatment of motor symptoms, but it is common for people with Parkinson's to take a combination of medications. Dopamine agonists are recommended as monotherapies in the early stages of the disease but in later stages as a combination or adjunct therapy with carbidopa/levodopa. They function like dopamine in the brain and improve the motor symptoms of individuals with Parkinson's, but they are less effective than levodopa. They have longer half-lives than levodopa and help reduce “off” time or enhance the benefits of levodopa. Many dopamine agonists were approved by the US FDA, like REQUIP, REQUIP XL (ropinirole), MIRAPEX, MIRAPEX ER (pramipexole), NEUPRO skin patch (rotigotine), and (APOKYN) apomorphine subcutaneous injection; however, they now have their generics in the market.

Parkinson's Disease Epidemiology

As the market is derived using a patient-based model, the Parkinson's disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Parkinson's disease, gender-specific diagnosed prevalent cases of Parkinson's disease, age-specific diagnosed prevalent cases of Parkinson's disease, and stage-specific diagnosed prevalent cases of Parkinson's disease in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
  • In 2022, the total diagnosed prevalent cases of Parkinson's disease were estimated to be approximately 2,539,400 cases in the 7MM. These cases are projected to increase during the forecast period (2023-2032).
  • In the US, there were approximately 1,152,195 diagnosed prevalent cases of Parkinson's disease in 2022. These were nearly 45% of the total cases in the 7MM. These cases are expected to increase during the forecast period.
Among gender-specific cases of Parkinson's disease, in the US, males accounted for 660,458 cases, while females accounted for approximately 491,736 cases in 2022. These cases are expected to change during the forecast period.
  • In 2022, EU4 and the UK accounted for nearly 47% of the total diagnosed prevalent cases of Parkinson's in the 7MM. These cases are anticipated to increase by 2032.
  • Among EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Parkinson's disease, nearly 38%, with approximately 454,448 cases, followed by France, with nearly 22%.
  • As per the report estimates, in EU4 and the UK, the age cohort =75 accounted for the highest diagnosed prevalent cases of Parkinson's, representing around 64% of the total cases, followed by the 65-74 age group with nearly 22% of the cases, and others, in 2022.
  • In 2022, among the 7MM, Japan had the fourth-highest diagnosed prevalent cases of Parkinson's disease, accounting for approximately 8% of the total cases in the 7MM.
  • In Japan, the gender-specific distribution of the disease suggests that more males were affected by Parkinson's disease than females in 2022, representing nearly 52% of the total cases. The gender-specific cases of Parkinson's disease are expected to increase during the forecast period.
According to estimates based on the publisher's epidemiology model for Parkinson's disease, in Japan, in 2022, the highest cases of Parkinson's disease were found in Stage III, i.e., approximately 83,477 cases, followed by 55,450 cases in Stage IV, 31,253 cases in Stage II, and others. These cases are expected to increase during the study period

Parkinson's Disease Drug Chapters

The drug chapter segment of the Parkinson's disease report encloses a detailed analysis of Parkinson's disease - currently used drugs and mid-stage (Phase II and Phase I) pipeline drugs. It also helps understand the Parkinson's disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/Zambon/Supernus Pharmaceuticals/Eisai

XADAGO tablets contain safinamide as the mesylate salt. The precise mechanism by which XADAGO exerts its effect on Parkinson's disease is unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity by blocking the catabolism of dopamine is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.

In September 2019, EQUFINA tablets 50 mg received approval in Japan for the improvement of the wearing-off phenomenon in patients with Parkinson's disease under the treatment with levodopa-containing preparations.

In March 2017, the US FDA approved XADAGO as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing “off” episodes.

In February 2015, XADAGO received marketing authorization in the European Union for treating adult patients with idiopathic Parkinson's disease as an add-on therapy to a stable dose of levodopa, alone or in combination with other Parkinson's medications, in mid-to late-stage Parkinson disease patients with motor fluctuations.

Note: Detailed marketed drugs assessment will be provided in the final report.

Emerging Drugs

SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/ Britannia Pharmaceutical

SPN-830 (apomorphine infusion device) is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease patients that are not adequately controlled with oral levodopa and one or more adjunct Parkinson's disease medications. SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14-18 h. Recently, the US FDA accepted the NDA filed by Supernus Pharmaceuticals for SPN-830, with the scheduled PDUFA date in 2024. In 2022, the US FDA issued a CRL to Supernus Pharmaceutical for the SPN-830 NDA, filled in September 2020. Prior to this, it had filed an NDA for which it received a refusal to file (RTF) letter. The drug completed a Phase III trial, and the company is anticipated to launch the SPN-830 in 2024.

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Although the current treatment landscape lacks curative therapy, many pharmacological and nonpharmacological options are tailored together to alleviate the symptoms of Parkinson's disease. Physical, occupational, and speech therapy can be critical to the treatment plan. Surgical options also have an important role for a subset of patients with Parkinson's disease, and complementary therapies can be used to treat some Parkinson's disease symptoms. Several classes of medications are available; however, carbidopa/levodopa remains the most effective symptomatic therapy and is available in many strengths and formulations.

Levodopa, developed around 30 years back, is often regarded as the gold standard of Parkinson's therapy. Levodopa works by crossing the blood-brain barrier, the elaborate meshwork of fine blood vessels and cells that filter blood reaching the brain, where it is converted into dopamine. Levodopa is extremely beneficial to people with Parkinson's disease and can dramatically improve their quality of life. However, the common side effects may include nausea, vomiting, dry mouth, and dizziness. Dyskinesias (abnormal movements) may occur as the dose is increased. In some patients, levodopa may cause confusion, hallucinations, or psychosis. INBRIJA is a widely used levodopa formulation.

To be continued in the report.

Parkinson's Disease Market Outlook

Although the current treatment landscape lacks curative therapy, many pharmacological and nonpharmacological options are tailored together to alleviate the symptoms of Parkinson's disease. Physical, occupational, and speech therapy can be critical to the treatment plan. Surgical options also have an important role for a subset of patients with Parkinson's disease, and complementary therapies can be used to treat some Parkinson's disease symptoms. Several classes of medications are available; however, carbidopa/levodopa remains the most effective symptomatic therapy and is available in many strengths and formulations.

Bromocriptine, pergolide, pramipexole, and ropinirole are dopamine agonists that mimic the role of chemical messengers in the brain, causing the neurons to react as they would to dopamine. They are prescribed alone or with levodopa and may be used in the early stages of the disease or administered to lengthen the duration of the effectiveness of levodopa. These medications generally have more side effects than levodopa, so that is taken into consideration before doctors prescribe dopamine agonists to patients. HARUROPI TAPE (ropinirole HCL), a systemic transdermal Parkinson's disease treatment patch developed by Hisamitsu Pharmaceutical, utilizing its TDDS technologies, is only authorized in Japan. KYNMOBI, a sublingual film containing apomorphine hydrochloride and a nonergoline dopamine agonist, was approved in the US in 2020; however, the company has discontinued the drug.

While there have been few major developments in Parkinson's disease treatment since the introduction of levodopa, several unmet need prevails. The current market of Parkinson's disease lacks curative and disease-modifying therapy, leaving symptomatic treatments with a multidisciplinary approach as the only option. Despite several decades of advances in medications and neurosurgical approaches, there remains an unmet need for symptomatic motor control. Better control of tremors, gait and balance, posture, dexterity, and communication skills are major challenges for better therapeutics of Parkinson's disease movement disorder. Further, treatment of psychosis is another unmet need of Parkinson's disease patients.

The current market has been covered by the symptomatic treatment that includes different pharmacological agents used across the 7MM, which presents minor variations in the overall prescription pattern. XADAGO/EQUFINA (safinamide), NOURIANZ/NOURIAST (istradefylline), DUOPA/DUODOPA (carbidopa and levodopa-ES), INBRIJA (levodopa), HARUROPI TAPE (ropinirole HCL), GOCOVRI (amantadine), and ONGENTYS (opicapone) are among the major drugs considered for in the Parkinson's disease forecast model.

Key players Supernus Pharmaceutical, Britannia Pharmaceutical, Cerevel Therapeutics, Pfizer, AbbVie, Pharma Two B, Annovis Bio, and others are evaluating their lead candidates in different stages of clinical development. They aim to investigate their products for the treatment of Parkinson's Disease and fulfill unmet needs.
  • The total market size of Parkinson's disease in the 7MM was approximately USD 2,936.3 million in 2022 and is projected to increase during the forecast period (2023-2032).
  • According to the publisher's estimates, among the 7MM, the US had the largest market share in Parkinson's disease, with a revenue of USD 1,760.7 million in 2022. The market size of Parkinson's disease in the US will increase at a significant CAGR due to increasing awareness of the disease and the growth of emerging and existing therapies.
  • In 2022, among the 7MM, the total market share of Parkinson's disease in EU4 and the UK was approximately 31%. Among EU4 and the UK countries, Germany accounted for the maximum market size of Parkinson's disease in 2022, while Italy occupied the bottom of the ladder.
  • Japan accounted for the third largest market size of Parkinson's disease among the 7MM, with a revenue of approximately USD 276.5 million in 2022, expected to increase during the forecast period.
  • As per the report estimates, in the 7MM, among the current therapies DUOPA/DUODOPA (carbidopa and levodopa-ES) and RYTARY (carbidopa and levodopa) accounted for the second and third highest market size with USD 353.8 million and USD 184.9 million in 2022, respectively. While, others and combination therapies had the highest market share, with nearly 65% of the total revenue in 2022.
  • The report estimates that Supernus Pharmaceuticals's GOCOVRI (amantadine) accounted for USD 104.4 million in the US in 2022. This revenue is projected to increase by 2032.
  • Various therapies like therapies in late-stages of development including Supernus Pharmaceutical and Britannia Pharmaceutical's SPN-830 (apomorphine infusion pump), Cerevel Therapeutics and Pfizer's tavapadon, AbbVie's ABBV-951 (foscarbidopa/ foslevodopa), Amneal Pharmaceuticals IPX203 (carbidopa/levodopa extended-release), Pharma Two B P2B001 (extended-release pramipexole and rasagiline), Mitsubishi Tanabe Pharma Corporation/NeuroDerm's ND0612 (levodopa/carbidopa), and Annovis Bio's Buntanetap (ANVS401/posiphen) are anticipated to enter the market during the forecast period.
  • SPN-830 (apomorphine infusion pump) and ND0612 (levodopa/carbidopa) are novel drug-device therapies. SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14-18 h, while ND0612 is a 24 h/day, continuous SC (subcutaneous) infusion of liquid levodopa/carbidopa (LD/CD).On the contrary, ABBV-951 is continuously administered into the abdomen for up to three consecutive days via an under-the-skin infusion set connected to a portable pump. The specialized pump designed for the drug allows patients to change infusion rates or doses. Despite a few product-related safety concerns, the drug will perform well during the forecast period due to its higher cost than other emerging therapies.
  • Mitsubishi Tanabe Pharma (NeuroDerm)'s ND0612 (levodopa/carbidopa) is designed to be user-friendly, compact, portable, and self-administered to reduce disease burden and improve the quality of life of people with Parkinson's and their families. Among the emerging therapies, it is expected to enter first in the market along with SPN-830 in 2024. ND0612 will have a slow medium uptake and will attain its peak in the eighth year.
  • IPX203 (carbidopa/levodopa extended-release), P2B001 (extended-release pramipexole and rasagiline), tavapadon, ABBV-951 (foscarbidopa/foslevodopa), and buntanetap (ANVS401/posiphen) are next in line with projected entry by 2026.
  • Annovis Bio's Buntanetap (ANVS401/posiphen) is a synthetically produced translational inhibitor of neurotoxic aggregating proteins (TINAPs), which lowers the level of neurotoxic proteins and consequently less toxicity in the brain. Good safety and efficacy along with convenient dosing, will translate to higher revenue, and with medium-fast uptake, it will attain its peak share by the seventh year.

Parkinson's Disease Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019-2032. For example, Pharma Two B's P2B001 (extended-release pramipexole and rasagiline), a once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose MAO-B inhibitor, with an anticipated entry by 2025 in the US, is predicted to have a slow-medium uptake during the forecast period.

Further detailed analysis of emerging therapies drug uptake in the report.

Parkinson's Disease Pipeline Development Activities

The report provides insights into therapeutic candidates in late-stage development (Phase III). It also analyzes key players involved in developing targeted therapeutics in different Phases of clinical trials.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for Parkinson's disease.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the Parkinson's disease evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

This analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like Johns Hopkins University School of Medicine, the University of California Davis School of Medicine, Université Bordeaux, IRCCS-Mario Negri Institute for Pharmacological Research, Hiroshima University, and the University of Cambridge were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Parkinson's disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

According to the primary research analysis, levodopa was the most common first-line Parkinson's disease treatment. Other commonly prescribed Parkinson's disease medications were pramipexole, entacapone combined with levodopa, ropinirole, and pergolide. Further, commonly prescribed adjunct therapies were monoamine oxidase type B inhibitors, non-ergot dopamine agonists, and zonisamide, regardless of age. Droxidopa and amantadine were prescribed as adjunct levodopa therapy slightly more frequently among elderly patients; levodopa adjunct therapy was prescribed when the levodopa dose was 300 mg, regardless of age.

The approval of emerging therapies and drugs that specifically target a-synuclein pathology, providing disease-modifying therapies for Parkinson's disease, will change the treatment regime and market dynamics for Parkinson's. Several regenerative approaches, including stem cells and gene therapies, and therapeutics for Parkinson's disease are likely to see significant advances over the coming years, with several novel, effective options likely to become available in the foreseeable future.

Qualitative Analysis

The publisher performs Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. To analyze the effectiveness of these therapies, have calculated their attributed analysis by giving them scores based upon change from baseline in the total “on” time and “off” time and change from baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The therapies' safety is evaluated wherein treatment-related and serious adverse events were majorly observed. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

In the case of Parkinson's disease, CMS covers a range of different treatments, medications, and services; Part A covers deep brain stimulation surgery, Part B: speech therapy and physical therapy, and Part C covers everything in the original Medicare (Part A and Part B); Part C: includes the additional drug coverage, and Part D: dopaminergic medications.

GOCOVRI is supported by GOCOVRI Onboard, a program designed to support patient access through one direct line of contact, copay assistance, and timely fulfillment. Further, to be eligible for the GOCOVRI Copay program, the patient must be a United States or Puerto Rico resident and have a valid GOCOVRI prescription for an indication included in the FDA-approved product labeling.

AccessOsmolex is a patient support services center focused on helping eligible patients obtain financial assistance for their OSMOLEX ER treatment plan. If the physician prescribes OSMOLEX ER for a patient, one must send the prescription to AccessOsmolex. Thus, AccessOsmolex will work with the office on coverage of OSMOLEX ER and with the patients to explain their coverage and affordability options.

INBRACE support program: The INBRACE Support Program is designed to help patients who are prescribed capsules, from prescription fulfillment to navigating coverage requirements and providing financial assistance information to support patients along their treatment journey.

ONGENTYS savings program for commercially insured patients: Eligible patients may qualify for a USD 0 copay on their prescription for ONGENTYS capsules. This offer is valid only for patients with commercial (nongovernment-funded) insurance. Additional terms and conditions apply.

ONGENTYS patient assistance program: Patients with no prescription drug coverage may be eligible to receive their prescriptions at no cost through the ONGENTYS Patient Assistance Program. Eligible patients who do not have prescription drug coverage for ONGENTYS and do not have the financial resources to pay for their medicine may receive their prescriptions at no cost through the ONGENTYS Patient Assistance Program.

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Parkinson's disease, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
  • Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
  • A detailed review of the Parkinson's disease market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Parkinson's disease market.

Parkinson's Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Parkinson's Disease Pipeline Analysis
  • Parkinson's Disease Market Size and Trends
  • Existing and Future Market Opportunity

Parkinson's Disease Report Key Strengths

  • Ten Years Forecast
  • The 7MM Coverage
  • Parkinson's Disease Epidemiology Segmentation
  • Key Cross Competition
  • Conjoint Analysis
  • Drugs Uptake and Key Market Forecast Assumptions

Parkinson's Disease Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered

Market Insights

  • What was the total market size of Parkinson's disease, the market size of Parkinson's disease by therapies, market share (%) distribution in 2019, and what would it look like by 2032? What are the contributing factors for this growth?
  • How will SPN-830 (apomorphine infusion device), tavapadon, ABBV-951 (foscarbidopa/foslevodopa), buntanetap (ANVS401/posiphen), and others affect the treatment paradigm of Parkinson's disease?
  • How will DUOPA/DUODOPA (carbidopa and levodopa-ES) compete with other off-label symptomatic treatments?
  • Which drug is going to be the largest contributor by 2032?
  • What are the pricing variations among different geographies for off-label therapies?
  • How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

  • What are the disease risks, burdens, and unmet needs of Parkinson's disease? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Parkinson's disease?
  • What is the historical and forecasted patient pool of Parkinson's disease in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
  • Out of the countries mentioned above, which country would have the highest diagnosed Parkinson's disease population during the forecast period (2023-2032)?
  • What factors are contributing to the growth of Parkinson's disease cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What are the current options for the treatment of Parkinson's disease?
  • How many companies are developing therapies for the treatment of Parkinson's disease?
  • How many emerging therapies are in the late, mid, and early stages of development for treating Parkinson's disease?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
  • What is the cost burden of current treatment on the patient?
  • Patient acceptability in terms of preferred treatment options as per real-world scenarios?
  • What are the accessibility issues of approved therapy in the US?
  • What is the 7MM historical and forecasted market of Parkinson's disease?

Reasons to Buy

  • The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Parkinson's disease market.
  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
  • The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
  • Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
  • Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
  • To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights2. Report Introduction
3. Parkinson’s Disease Market Overview at a Glance
3.1. Market Share (%) Distribution of Parkinson’s Disease in 2019
3.2. Market Share (%) Distribution of Parkinson’s Disease in 2032
4. Methodology of Parkinson’s Disease Epidemiology and Market5. Executive Summary of Parkinson’s Disease6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Classification
7.3. Signs and Symptoms
7.4. Risk Factors
7.5. Pathophysiology
7.6. Diagnosis
7.6.1. Biomarker
7.6.2. Diagnostic Guidelines
7.6.2.1. American Academy of Family Physicians
7.6.2.2. European Federation of Neurological Societies/Movement Disorder Society- European Section (EFNS/MDS-ES) Recommendations for the Diagnosis of Parkinson’s Disease
7.6.2.3. The National Institute for Health and Care Excellence (NICE): Recommendation for Diagnosis of Parkinson’s Disease
7.6.2.4. Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson’s Disease
7.6.3. Diagnostic Algorithm
7.6.4. Differential Diagnosis
7.7. Treatment
7.7.1. Treatment Algorithm
7.7.2. Treatment Guidelines
7.7.2.1. National Institute for Health and Care Excellence (NICE): Recommendation for Parkinson’s disease
7.7.2.2. American Academy of Neurology (AAN) Guidelines for Treatment of Early Parkinson’s Disease
7.7.2.3. Clinical Practice Guidelines by the NHS Spain
7.7.2.4. Clinical Practice Guidelines by the Japanese Society of Neurology (JSN)
8. Patient Journey
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: The 7MM
9.2.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease
9.2.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease
9.2.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease
9.2.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease
9.3. Total Diagnosed Prevalent Cases of Parkinson’s Disease in the 7MM
9.4. The US
9.4.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease in the US
9.4.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US
9.4.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US
9.4.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US
9.5. EU4 and the UK
9.5.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
9.5.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
9.5.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
9.5.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK
9.6. Japan
9.6.1. Total Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
9.6.2. Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
9.6.3. Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
9.6.4. Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan
10. Marketed Drugs
10.1. Key Cross Competition
10.2. XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/Zambon/Supernus Pharmaceuticals/Eisai
10.2.1. Drug Description
10.2.2. Other Development Activities
10.2.3. Regulatory Milestones
10.2.4. Clinical Development
10.2.5. Clinical Trial Information
10.2.6. Safety and Efficacy
10.2.7. Product Profile
10.3. NOURIANZ/NOURIAST (istradefylline): Kyowa Kirin
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Other Development Activities
10.3.4. Clinical Development
10.3.5. Clinical Trial Information
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.4. DUOPA/DUODOPA (carbidopa and levodopa-ES): AbbVie
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Other Development Activities
10.4.4. Clinical Development
10.4.5. Clinical Trial Information
10.4.6. Safety and Efficacy
10.4.7. Product Profile
10.5. INBRIJA (levodopa): Acorda Therapeutics/Esteve Pharmaceuticals
10.5.1. Drug Description
10.5.2. Regulatory milestones
10.5.3. Other Development Activities
10.5.4. Clinical Development
10.5.5. Clinical Trial Information
10.5.6. Safety and Efficacy
10.5.7. Product Profile
10.6. GOCOVRI (amantadine): Supernus Pharmaceuticals
10.6.1. Drug Description
10.6.2. Regulatory Milestones
10.6.3. Other Development Activities
10.6.4. Clinical Development
10.6.5. Clinical Trial Information
10.6.6. Safety and Efficacy
10.6.7. Product Profile
10.7. ONGENTYS (opicapone): Neurocrine Biosciences/BIAL/Ono Pharmaceutical
10.7.1. Drug Description
10.7.2. Regulatory Milestones
10.7.3. Other Development Activities
10.7.4. Clinical Development
10.7.5. Clinical Trial Information
10.7.6. Safety and Efficacy
10.7.7. Product Profile
10.8. OSMOLEX ER (amantadine): Supernus Pharmaceuticals
10.8.1. Drug Description
10.8.2. Regulatory Milestone
10.8.3. Other Development Activities
10.8.4. Clinical Development
10.8.5. Clinical Trial Information
10.8.6. Safety and Efficacy
10.8.7. Product Profile
10.9. RYTARY (carbidopa and levodopa): Amneal Pharmaceuticals
10.9.1. Product Description
10.9.2. Regulatory Milestone
10.9.3. Other Development Activities
10.9.4. Clinical Development
10.9.5. Clinical Trial Information
10.9.6. Safety and Efficacy
10.9.7. Product Profile
10.10. AZILECT (rasagiline mesylate): Teva Pharmaceuticals/ Lundbeck/Takeda
10.10.1. Drug Description
10.10.2. Regulatory Milestones
10.10.3. Other Development Activities
10.10.4. Clinical Development
10.10.5. Clinical Trial Information
10.10.6. Safety and efficacy
10.10.7. Product Profile
10.11. HARUROPI TAPE (ropinirole HCL): Hisamitsu Pharmaceutical/Kyowa Kirin
10.11.1. Drug Description
10.11.2. Regulatory Milestones
10.11.3. Other Development Activities
10.11.4. Safety and Efficacy
10.11.5. Product Profile
11. Emerging Drugs
11.1. Key Cross Competition
11.2. SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/ Britannia Pharmaceutical
11.2.1. Drug Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.2.7. Analyst Comments
11.3. Tavapadon: Cerevel Therapeutics/Pfizer
11.3.1. Drug Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.3.7. Analyst Comments
11.4. ABBV-951 (foscarbidopa/foslevodopa): AbbVie
11.4.1. Drug description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.4.7. Analyst Comment
11.5. IPX203 (carbidopa/levodopa extended-release): Amneal Pharmaceuticals
11.5.1. Drug Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Safety and Efficacy
11.5.6. Product Profile
11.5.7. Analyst Comments
11.6. P2B001 (extended-release pramipexole and rasagiline): Pharma Two B
11.6.1. Drug Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.6.7. Analyst Comment
11.7. ND0612 (levodopa/carbidopa): Mitsubishi Tanabe Pharma (NeuroDerm)
11.7.1. Drug Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.7.7. Analyst Comments
11.8. Buntanetap (ANVS401/posiphen): Annovis Bio
11.8.1. Drug Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.4. Clinical Trials Information
11.8.5. Safety and Efficacy
11.8.6. Product Profile
11.8.7. Analyst Comments
12. Parkinson’s Disease: Market Analysis
12.1. Key Findings
12.2. Key Market Forecast Assumptions
12.3. Market Outlook
12.4. Conjoint Analysis
12.5. Total Market Size of Parkinson’s Disease in the 7MM
12.6. Total Market Size of Parkinson’s Disease by Therapies in the 7MM
12.7. Market Size of Parkinson’s Disease in the US
12.7.1. Total Market Size of Parkinson’s Disease in the US
12.7.2. The Market Size of Parkinson’s Disease by Therapies in the US
12.8. Market Size of Parkinson’s Disease in EU4 and the UK
12.8.1. Total Market Size of Parkinson’s Disease in EU4 and the UK
12.8.2. The Market Size of Parkinson’s Disease by Therapies in EU4 and the UK
12.9. Market Size of Parkinson’s Disease in Japan
12.9.1. Total Market Size of Parkinson’s Disease in Japan
12.9.2. The Market Size of Parkinson’s Disease by Therapies in Japan
13. Key Opinion Leaders’ Views14. SWOT Analysis15. Unmet need
16. Market Access and Reimbursement
16.1. The United States
16.1.1. Center for Medicare and Medicaid Services (CMS)
16.2. In EU4 and the UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. The United Kingdom
16.3. Japan
16.3.1. MHLW
17. Appendix
17.1. Bibliography
17.2. Acronyms and Abbreviations
17.3. Report Methodology
18. Publisher Capabilities19. Disclaimer20. About the Publisher
List of Tables
Table 1: Summary of Market and Epidemiology (2019-2032)
Table 2: Signs and Symptoms of Parkinson’s Disease
Table 3: Differential Diagnosis of Parkinsonism
Table 4: Potential Benefits and Harms of Dopamine Agonists, Levodopa, and MAO B inhibitors
Table 5: Potential Benefits and Harms of Dopamine Agonists, COMT Inhibitors, and Amantadine
Table 6: Pharmacological Management of Non-motor Symptoms
Table 7: Nonpharmacological Management of motor and non-motor symptoms
Table 8: AAN Guidelines for the Treatment of Early Parkinson’s Disease
Table 9: NHS Spain - Motor Symptoms Recommendations for Treatment of Parkinson’s Disease
Table 10: NHS Spain - Non-motor Symptoms Recommendations for Treatment of Parkinson’s Disease
Table 11: NHS Spain - Recommendations for Treatment of Parkinson’s Disease (Nonpharmacological)
Table 12: Recommendations for Treatment of Parkinson’s Disease - Speech Therapy
Table 13: Recommendations for Treatment of Parkinson’s Disease - Nutrition and Diet
Table 14: Recommendations for Treatment of Parkinson’s Disease by JSN - 2011 Update
Table 15: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the 7MM (2019-2032)
Table 16: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 17: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 18: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 19: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Table 20: Total Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 21: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 22: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 23: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 25: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 26: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 27: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Table 28: Key Cross of Marketed Drugs
Table 29: XADAGO/EQUFINA (safinamide), Clinical Trial Description, 2023
Table 30: NOURIANZ/NOURIAST (istradefylline), Clinical Trial Description, 2023
Table 31: DUOPA/DUODOPA (carbidopa and levodopa-ES), Clinical Trial Description, 2023
Table 32: INBRIJA (levodopa), Clinical Trial Description, 2023
Table 33: GOCOVRI (amantadine), Clinical Trial Description, 2023
Table 34: ONGENTYS (opicapone), Clinical Trial Description, 2023
Table 35: OSMOLEX ER (amantadine), Clinical Trial Description, 2023
Table 36: RYTARY (carbidopa and levodopa), Clinical Trial Description, 2023
Table 37: AZILECT (rasagiline mesylate), Clinical Trial Description, 2023
Table 38: Comparison of Emerging Drugs for Treatment
Table 39: SPN-830 (apomorphine infusion device), Clinical Trial Description, 2023
Table 40: Tavapadon, Clinical Trial Description, 2023
Table 41: ABBV-951 (foscarbidopa/foslevodopa), Clinical Trial Description, 2023
Table 42: IPX203 (carbidopa/levodopa extended-release), Clinical Trial Description, 2023
Table 43: P2B001 (extended-release pramipexole and rasagiline), Clinical Trial Description, 2023
Table 44: ND0612 (levodopa/carbidopa), Clinical Trial Description, 2023
Table 45: Buntanetap (ANVS401/posiphen), Clinical Trial Description, 2023
Table 46: Key Market Forecast Assumptions for SPN-830 (Apomorphine Infusion Pump)
Table 47: Key Market Forecast Assumptions for Tavapadon
Table 48: Key Market Forecast Assumptions for ABBV-951 (foscarbidopa/foslevodopa)
Table 49: Key Market Forecast Assumptions for IPX203 (carbidopa/levodopa extended-release)
Table 50: Key Market Forecast Assumptions for P2B001 (extended-release pramipexole and rasagiline)
Table 51: Key Market Forecast Assumptions for ND0612 (levodopa/carbidopa)
Table 52: Key Market Forecast Assumptions for Buntanetap (ANVS401/posiphen)
Table 53: Total Market Size of Parkinson’s Disease in the 7MM, in USD million (2019-2032)
Table 54: Total Market Size of Parkinson’s Disease by Therapies in the 7MM, in USD million (2019-2032)
Table 55: Total Market Size of Parkinson’s Disease in the US, in USD million (2019-2032)
Table 56: The Market Size of Parkinson’s Disease by Therapies in the US, in USD million (2019-2032)
Table 57: Total Market Size of Parkinson’s Disease in EU4 and the UK, in USD million (2019-2032)
Table 58: The Market Size of Parkinson’s Disease by Therapies in EU4 and the UK, in USD million (2019-2032)
Table 59: Total Market Size of Parkinson’s Disease in Japan, in USD million (2019-2032)
Table 60: The Market Size of Parkinson’s Disease by Therapies in Japan, in USD million (2019-2032)
List of Figures
Figure 1: Classification of Parkinson’s Disease
Figure 2: Clinical Manifestations in Parkinson’s Disease
Figure 3: Risk Factors Involved in Parkinson’s Disease
Figure 4: Genes Involved in Parkinson’s Disease
Figure 5: Mechanisms of Neurodegeneration in Parkinson’s Disease
Figure 6: QSBB Criteria for the Diagnosis of Parkinson’s Disease
Figure 7: MDS Clinical Diagnostic Criteria for Parkinson’s Disease
Figure 8: AAFP Diagnostic Algorithm for Parkinson’s Disease
Figure 9: Treatment for Parkinson’s Disease
Figure 10: Mechanism of Action of Levodopa
Figure 11: Dopamine Agonists for the Treatment of Parkinson’s Disease
Figure 12: Treatment Algorithm for Parkinson’s Disease
Figure 13: Patient Journey
Figure 14: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the 7MM (2019-2032)
Figure 15: Total Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 16: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 17: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 18: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in the US (2019-2032)
Figure 19: Total Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 20: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 21: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 22: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in EU4 and the UK (2019-2032)
Figure 23: Total Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 24: Gender-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 25: Age-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 26: Stage-specific Diagnosed Prevalent Cases of Parkinson’s Disease in Japan (2019-2032)
Figure 27: Total Market Size of Parkinson’s Disease in the 7MM, in USD million (2019-2032)
Figure 28: Total Market Size of Parkinson’s Disease by Therapies in the 7MM, in USD million (2019-2032)
Figure 29: Total Market Size of Parkinson’s Disease in the US, in USD million (2019-2032)
Figure 30: The Market Size of Parkinson’s Disease by Therapies in the US, in USD million (2019-2032)
Figure 31: Total Market Size of Parkinson’s Disease in EU4 and the UK, in USD million (2019-2032)
Figure 32: The Market Size of Parkinson’s Disease by Therapies in EU4 and the UK, in USD million (2019-2032)
Figure 33: Total Market Size of Parkinson’s Disease in Japan, in USD million (2019-2032)
Figure 34: The Market Size of Parkinson’s Disease by Therapies in Japan, in USD million (2019-2032)
Figure 35: SWOT Analysis of Parkinson’s Disease
Figure 36: Unmet Needs of Parkinson’s Disease
Figure 37: Health Technology Assessment
Figure 38: Reimbursement Process in Germany
Figure 39: Reimbursement Process in France
Figure 40: Reimbursement Process in Italy
Figure 41: Reimbursement Process in Spain
Figure 42: Reimbursement Process in the United Kingdom
Figure 43: Reimbursement Process in Japan

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Supernus Pharmaceutical
  • Britannia Pharmaceutical
  • Cerevel Therapeutics
  • Pfizer
  • AbbVie
  • Amneal Pharmaceuticals
  • Pharma Two B
  • Mitsubishi Tanabe Pharma (NeuroDerm)
  • Annovis Bio